102438-99-3Relevant articles and documents
Silicon analogues of the nonpeptidic GnRH antagonist AG-045572: Syntheses, crystal structure analyses, and pharmacological characterization
Barnes, Matthew J.,Burschka, Christian,Buettner, Matthias W.,Conroy, Richard,Daiss, Juergen O.,Gray, Ian C.,Hendrick, Alan G.,Tam,Kuehn, Diana,Miller, David J.,Mills, John S.,Mitchell, Philip,Montana, John G.,Muniandy, Parameswary A.,Rapley, Helen,Showell, Graham A.,Tebbe, David,Tacke, Reinhold,Warneck, Julie B.H.,Zhu, Bin
, p. 2070 - 2080 (2011)
AG-045572 (CMPD1, 1a) is a nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist that has been investigated for the treatment of sex hormone-related diseases. In the context of systematic studies on sila-substituted drugs, the silicon analogue disila-AG-045572 (1b) and its derivative 2 were prepared in multi-step syntheses and characterized by elemental analyses (C, H, N), NMR spectroscopic studies (1H, 13C, 29Si), and single-crystal X-ray diffraction. The pharmacological properties of compounds 1a, 1b, and 2 were compared in terms of their in vitro potency at cloned human and rat GnRH receptors. Compounds 1a and 2 were also examined in regard to their pharmacokinetics and in vivo efficacy in both castrated rat (luteinizing hormone (LH) suppression) and intact rat (testosterone suppression) models. The efficacy and pharmacokinetic profiles of 1a and its silicon-containing analogue 2 appear similar, indicating that replacement of the 5,6,7,8-tetrahydronaphthalene ring system by the 1,3-disilaindane skeleton led to retention of efficacy. Therefore, the silicon compound 2 represents a novel drug prototype for the design of potent, orally available GnRH antagonists suitable for once-daily dosing.
